Literature DB >> 24943499

Accumulation of trans-1-amino-3-[(18)F]fluorocyclobutanecarboxylic acid in prostate cancer due to androgen-induced expression of amino acid transporters.

Hiroyuki Okudaira1, Shuntaro Oka, Masahiro Ono, Takeo Nakanishi, David M Schuster, Masato Kobayashi, Mark M Goodman, Ikumi Tamai, Keiichi Kawai, Yoshifumi Shirakami.   

Abstract

PURPOSE: Androgens play a crucial role in prostate cancer progression, and trans-1-amino-3-[(18)F]fluorocyclobutanecarboxylic acid (anti-[(18) F]FACBC) are used for visualization of prostate cancer. We examined the effect of androgen on the expression of amino acid transporters related to anti-[(18)F]FACBC transport and uptake of trans-1-amino-3-fluoro-[1-(14)C]cyclobutanecarboxylic acid (anti-[(14)C]FACBC). PROCEDURES: Expression of amino acid transporters and uptake of anti-[(14)C]FACBC in androgen receptor (AR)-positive LNCaP and AR-negative DU145 human prostate cancer cells cultured with/without 5α-dihydrotestosterone (DHT) and the effect of bicalutamide, an AR antagonist, on DHT-associated changes were investigated.
RESULTS: DHT stimulated the expression of amino acid transporters ASCT2, SNAT5, 4F2 heavy chain, and LAT3 in LNCaP but not in DU145 cells. Anti-[(14)C]FACBC uptake was enhanced, in a DHT-dependent manner, in LNCaP cells only.
CONCLUSIONS: DHT enhanced the expression of ASCT2, the transporter responsible for anti-[(18)F]FACBC uptake, thereby increasing anti-[(14)C]FACBC uptake in AR-positive LNCaP cells. Androgen-mediated induction may contribute to the distinct anti-[(18)F]FACBC accumulation pattern in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24943499      PMCID: PMC5648589          DOI: 10.1007/s11307-014-0756-x

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  35 in total

Review 1.  Solute carrier transporters as targets for drug delivery and pharmacological intervention for chemotherapy.

Authors:  Takeo Nakanishi; Ikumi Tamai
Journal:  J Pharm Sci       Date:  2011-05-31       Impact factor: 3.534

2.  Identification of a novel transcript up-regulated in a clinically aggressive prostate carcinoma.

Authors:  R F Chuaqui; C R Englert; S E Strup; C D Vocke; Z Zhuang; P H Duray; D G Bostwick; W M Linehan; L A Liotta; M R Emmert-Buck
Journal:  Urology       Date:  1997-08       Impact factor: 2.649

3.  Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression.

Authors:  Qian Wang; Charles G Bailey; Cynthia Ng; Jessamy Tiffen; Annora Thoeng; Vineet Minhas; Melanie L Lehman; Stephen C Hendy; Grant Buchanan; Colleen C Nelson; John E J Rasko; Jeff Holst
Journal:  Cancer Res       Date:  2011-10-17       Impact factor: 12.701

4.  Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT.

Authors:  David M Schuster; Bital Savir-Baruch; Peter T Nieh; Viraj A Master; Raghuveer K Halkar; Peter J Rossi; Melinda M Lewis; Jonathon A Nye; Weiping Yu; F DuBois Bowman; Mark M Goodman
Journal:  Radiology       Date:  2011-04-14       Impact factor: 11.105

5.  Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma.

Authors:  David M Schuster; John R Votaw; Peter T Nieh; Weiping Yu; Jonathon A Nye; Viraj Master; F DuBois Bowman; Muta M Issa; Mark M Goodman
Journal:  J Nucl Med       Date:  2007-01       Impact factor: 10.057

6.  Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction.

Authors:  David R Wise; Ralph J DeBerardinis; Anthony Mancuso; Nabil Sayed; Xiao-Yong Zhang; Harla K Pfeiffer; Ilana Nissim; Evgueni Daikhin; Marc Yudkoff; Steven B McMahon; Craig B Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-24       Impact factor: 11.205

Review 7.  Molecular imaging of prostate cancer with PET.

Authors:  Hossein Jadvar
Journal:  J Nucl Med       Date:  2013-10       Impact factor: 10.057

Review 8.  Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond.

Authors:  Vadivel Ganapathy; Muthusamy Thangaraju; Puttur D Prasad
Journal:  Pharmacol Ther       Date:  2008-11-01       Impact factor: 12.310

9.  Androgen-regulated genes in the murine epididymis.

Authors:  Theodore R Chauvin; Michael D Griswold
Journal:  Biol Reprod       Date:  2004-04-28       Impact factor: 4.285

10.  Choline PET and PET/CT in Primary Diagnosis and Staging of Prostate Cancer.

Authors:  S Schwarzenböck; M Souvatzoglou; B J Krause
Journal:  Theranostics       Date:  2012-03-15       Impact factor: 11.556

View more
  13 in total

Review 1.  PET Tracers Beyond FDG in Prostate Cancer.

Authors:  David M Schuster; Cristina Nanni; Stefano Fanti
Journal:  Semin Nucl Med       Date:  2016-09-07       Impact factor: 4.446

2.  [18F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging-version 1.0.

Authors:  Cristina Nanni; Lucia Zanoni; Tore Bach-Gansmo; Heikki Minn; Frode Willoch; Trond Velde Bogsrud; Ephraim Parent Edward; Bital Savir-Baruch; Eugene Teoh; Fenton Ingram; Stefano Fanti; David M Schuster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-11       Impact factor: 9.236

3.  Prospective evaluation of fluciclovine (18F) PET-CT and MRI in detection of recurrent prostate cancer in non-prostatectomy patients.

Authors:  Oladunni Akin-Akintayo; Funmilayo Tade; Pardeep Mittal; Courtney Moreno; Peter T Nieh; Peter Rossi; Dattatraya Patil; Raghuveer Halkar; Baowei Fei; Viraj Master; Ashesh B Jani; Hiroumi Kitajima; Adeboye O Osunkoya; Claudia Ormenisan-Gherasim; Mark M Goodman; David M Schuster
Journal:  Eur J Radiol       Date:  2018-02-24       Impact factor: 3.528

Review 4.  Molecular Imaging Assessment of Androgen Deprivation Therapy in Prostate Cancer.

Authors:  Hossein Jadvar; Patrick M Colletti
Journal:  PET Clin       Date:  2022-05-31

5.  Selective modification of fluciclovine (18F) transport in prostate carcinoma xenografts.

Authors:  F I Tade; W G Wiles; G Lu; B Bilir; O Akin-Akintayo; J S Lee; D Patil; W Yu; C Ormenisan Gherasim; B Fei; C S Moreno; A O Osunkoya; E J Teoh; S Oka; H Okudaira; M M Goodman; D M Schuster
Journal:  Amino Acids       Date:  2018-06-15       Impact factor: 3.520

6.  Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.

Authors:  Oluwaseun A Odewole; Funmilayo I Tade; Peter T Nieh; Bital Savir-Baruch; Ashesh B Jani; Viraj A Master; Peter J Rossi; Raghuveer K Halkar; Adeboye O Osunkoya; Oladunni Akin-Akintayo; Chao Zhang; Zhengjia Chen; Mark M Goodman; David M Schuster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-04-18       Impact factor: 9.236

Review 7.  Tumour metabolism and its unique properties in prostate adenocarcinoma.

Authors:  David A Bader; Sean E McGuire
Journal:  Nat Rev Urol       Date:  2020-02-28       Impact factor: 14.432

8.  Image Guided Planning for Prostate Carcinomas With Incorporation of Anti-3-[18F]FACBC (Fluciclovine) Positron Emission Tomography: Workflow and Initial Findings From a Randomized Trial.

Authors:  Eduard Schreibmann; David M Schuster; Peter J Rossi; Joseph Shelton; Sherrie Cooper; Ashesh B Jani
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-04-30       Impact factor: 7.038

9.  Positron Emission Tomography in Prostate Cancer: Summary of Systematic Reviews and Meta-Analysis.

Authors:  Hossein Jadvar
Journal:  Tomography       Date:  2015-09

Review 10.  Fluciclovine positron emission tomography in the setting of biochemical recurrence following local therapy of prostate cancer.

Authors:  Zachary A Glaser; Soroush Rais-Bahrami
Journal:  Transl Androl Urol       Date:  2018-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.